January 04, 2019
1 min read
Save

Top gastroenterology stories: Antidepressants may impact IBD, patient activation linked to IBD remission

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Among the top stories in gastroenterology this past week was research indicating that antidepressants could impact disease course in inflammatory bowel disease and patients who had a more active role in the management of their IBD experienced better disease severity.

Other popular stories included data indicating that Wide Area Transepithelial Sampling with 3D Tissue Analysis, , helps increase detection of esophageal dysplasia and Barrett’s esophagus, a report detailing a phase 3 trial to test metastatic colorectal cancer treatment and findings showing that patients with IBD have a greater risk for postcolonoscopy colorectal cancer. – by Alaina Tedesco

Antidepressants could impact disease course in IBD

Antidepressants could be a beneficial therapy for patients with IBD for symptoms beyond anxiety and depression, according to research published in Inflammatory Bowel Diseases. Read more.

Patient activation linked to clinical remission in IBD

Patients with IBD who were more knowledgeable about and had a more active role in the management of their disease experienced better disease severity, according to research published in Inflammatory Bowel Diseases. Read more.

WATS3D helps increase detection of esophageal dysplasia, Barrett’s

Adding Wide Area Transepithelial Sampling with 3D Tissue Analysis, or WATS3D, to standard targeted and random forceps biopsy helped increase detection of esophageal dysplasia, as well as Barrett’s esophagus, according to research published in Diseases of the Esophagus. Read more.

Phase 3 trial to test metastatic colorectal cancer treatment

The first patient has enrolled in a phase 3 trial that will test arfolitixorin for the treatment of metastatic colorectal cancer, according the manufacturer, Isofol Medical AB. Read more.

Patients with IBD at greater risk for postcolonoscopy colorectal cancer

Patients with IBD experience higher rates of postcolonoscopy colorectal cancer, a risk that is higher among younger patients with ulcerative colitis and an additional risk for rectal cancers among those with Crohn’s disease, according to research published in Gut. Read more.